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Abstract
Background & Aims—Liver biopsy, the gold standard for assessing liver fibrosis, suffers from 
limitations due to sampling error and invasiveness. There is therefore a critical need for methods 
to non-invasively quantify fibrosis throughout the entire liver. The goal of this study was to use 
molecular Magnetic Resonance Imaging (MRI) of Type I collagen to non-invasively image liver 
fibrosis and assess response to rapamycin therapy.
Methods—Liver fibrosis was induced in rats by bile duct ligation (BDL). MRI was performed 4, 
10, or 18 days following BDL. Some BDL rats were treated daily with rapamcyin starting on day 
4 and imaged on day 18. A three-dimensional (3D) inversion recovery MRI sequence was used to 
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quantify the change in liver longitudinal relaxation rate (ΔR1) induced by the collagen-targeted 
probe EP-3533. Liver tissue was subjected to pathologic scoring of fibrosis and analyzed for Sirius 
Red staining and hydroxyproline content.
Results—ΔR1 increased significantly with time following BDL compared to controls in 
agreement with ex vivo measures of increasing fibrosis. Receiver operating characteristic curve 
analysis demonstrated the ability of ΔR1 to detect liver fibrosis and distinguish intermediate and 
late stages of fibrosis. EP-3533 MRI correctly characterized the response to rapamycin in 11 out 
of 12 treated rats compared to the standard of collagen proportional area (CPA). 3D MRI enabled 
characterization of disease heterogeneity throughout the whole liver.
Conclusions—EP-3533 allowed for staging of liver fibrosis, assessment of response to 
rapamycin therapy, and demonstrated the ability to detect heterogeneity in liver fibrosis.
Keywords
Liver fibrosis; Type I collagen; Molecular imaging; Non-invasive; MRI; EP-3533; Bile duct 
ligation (BDL)
Introduction
Chronic liver disease is a major cause of morbidity and mortality worldwide, and unlike 
other major causes of mortality, rates of chronic liver disease are increasing rather than 
declining [1]. Chronic liver disease results from a wide range of etiological factors including 
viral hepatitis, metabolic dysfunction, alcohol abuse and autoimmune disease. Liver fibrosis 
is the common result of virtually all chronic liver injuries [2]. During fibrosis, the ongoing 
cycles of injury and repair lead to accumulation of extracellular matrix (ECM) components 
rich in fibrillar collagen, and eventually disruption of normal tissue architecture and function 
[3]. If the underlying cause of disease is suppressed or removed early enough, liver fibrosis 
has the potential to regress to a lesser stage or even reverse to a normal architecture [4, 5]. 
However, if left unchecked, fibrosis will progress to cirrhosis, an advanced stage of the 
disease estimated to affect 1-2% of the world’s population [6, 7]. Accurate assessment of 
fibrosis stage and early detection of cirrhosis are therefore vital for determining prognosis 
and guiding management, since doing so identifies those patients at greatest risk of 
developing complications of cirrhosis for which longitudinal survey is essential.
Biopsy is an imperfect gold standard in assessing liver fibrosis as it suffers from intra/inter-
observer variability and is associated with several complications including hospitalization in 
1-5% cases and mortality in 0.01-0.1% of cases [8, 9]. In addition, sampling error is a major 
issue as the 1-2 pieces of 1 cm long liver biopsies only assess 1/50,000 of the liver volume 
[10]. Importantly, repeated biopsies to evaluate disease progression or response to treatment 
are impractical due to the increased risk of complications and poor patient compliance. For 
all of these reasons, non-invasive strategies that can repeatedly assess liver fibrosis 
throughout the entire organ are urgently needed to assess disease stage, monitor treatment 
response and determine prognosis.
Type I collagen is an attractive target for molecular imaging of fibrosis since collagen 
deposition is a common outcome regardless of fibrosis cause. Moreover, the collagen 
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concentration increases as fibrosis progresses and its extracellular location makes it readily 
accessible by the probe. We have previously reported data with a peptide-based Type I 
collagen-specific MR probe, termed EP-3533, for detection and quantification of fibrosis, 
and demonstrated its utility in cardiac, pulmonary and hepatic models of fibrosis [11-15]. In 
the liver, molecular imaging of collagen with EP-3533 was much more sensitive to the 
presence of fibrosis than other MRI measures such as water diffusion and could accurately 
stage liver fibrosis [14]. EP-3533 was calculated to have a blood half-life of 19±2 min in 
both fibrotic and control mice consistent with its extracellular distribution and primary renal 
clearance [14]. By 24 h, the probe was largely eliminated from the body. When tested at 10 
μM in a “lead side-effect panel” of 33 different in vitro assays, EP-3533 had no measurable 
effect in terms of inhibiting receptor binding [14]. These pharmacokinetics, biodistribution, 
and in vitro pharmacology studies suggest the potential of this probe for translation to 
human studies.
Here, we expand upon these studies and demonstrate that EP-3533 can accurately stage 
biliary fibrosis in bile duct ligated (BDL) rats. While our initial studies were performed on 
high field small animal scanners, we now show efficacy using a 1.5-tesla clinical MRI 
scanner in order to further clinical translation. In addition, our previous studies quantified 
changes in the contrast-to-noise ratio (ΔCNR) between liver and adjacent skeletal muscle 
after injection of EP-3533 and were typically performed on a just a few liver image slices 
[11-14]. In the current work we have made fibrosis quantification more extensive by 
introducing a respiratory-gated three dimensional (3D) inversion recovery imaging sequence 
that allows us to measure the change in longitudinal relaxation rate (ΔR1) induced by 
EP-3533 on a pixel-wise basis throughout the entire liver. Since ΔR1 is linearly proportional 
to the Gadolinium concentration, it has the potential to provide a more quantitative and 
robust metric than ΔCNR for the assessment of fibrosis, and to measure disease 
heterogeneity within the liver. In order to test this, we measured fibrosis in rapamycin 
treated BDL rats where considerable variability was observed previously in liver fibrosis 
response to rapamycin [16, 17]. The rapamycin experiments therefore provided a rigorous 
test of the ability of EP-3533 to detect differences in disease progression and response to 
therapy.
Materials and Methods
Animal Model
Liver fibrosis was induced in male CD rats (n=39) by ligation of the common bile duct 
(Charles River Labs, Wilmington, MA). Control animals (n=8) underwent a control 
procedure. BDL rats were imaged 4 (n=9), 10 (n=10), or 18 (n=8) days following ligation. 
Rapamycin treated rats (n=12) were administered 3 mg/kg/day by oral gavage starting on 
day 4 and were imaged on day 18. EP-3533 was prepared as reported previously [11]. All 
experiments and procedures were performed in accordance with the NIH Guide for the Care 
and Use of Laboratory Animals and were approved by the Massachusetts General Hospital 
Institutional Animal Care and Use Committee.
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Magnetic Resonance Imaging
Rats were imaged on a 1.5-tesla clinical MRI scanner (Siemens Healthcare, Malvern, PA) 
using a home-built, transmit-receive solenoid coil (Supplementary Fig. 1). Animals were 
anesthetized with 1-2% isoflurane and respiration rate was monitored with a small animal 
physiological monitoring system (SA Instruments, Inc., Stony Brook, NY). 
Respiratorygated, 3D Inversion Recovery (IR) Fast Low Angle Shot (FLASH) images were 
acquired prior to and 1 hour following intravenous administration of 10 μmol/kg EP-3533. A 
non-selective inversion pulse was used and images were acquired with inversion recovery 
times of 50, 100, 200, 250, 300, 400 and 1000 ms. Image acquisition parameters consisted of 
an echo time of TE = 2.44 ms, field-of-view FOV = 120×93 mm, matrix = 192×150 (0.625 
mm inplane resolution), slice thickness = 0.6 mm, and 36 image slices. A segmented k-space 
acquisition method consisting of 51 segments was used to reduce the acquisition time. The 
effective repetition time was dictated by the respiration rate. Anesthesia was adjusted to 
maintain a respiration rate of 60±5 breaths per minute for an effective repetition time of 
TReff = 1000±90 ms. Following imaging, animals were sacrificed and liver tissue was 
subjected to pathologic scoring of fibrosis and analyzed for hydroxyproline content. 
Longitudinal relaxation rate (R1) maps were generated from the images using a custom 
written MATLAB (Mathworks, Natick, MA) program for voxel wise fitting of the inversion 
recovery signal intensities as a function of the inversion recovery time.
Ex Vivo Tissue Analysis
Formalin-fixed samples were embedded in paraffin, cut into 5 μm-thick sections and stained 
with Sirius Red according to standard procedures. Sirius Red stained sections were analyzed 
by a pathologist, who was blinded to the study, to score the amount of liver disease 
according to the method of Ishak [18]. In addition, the Collagen Proportional Area (CPA), as 
determined by the % area stained with Sirius Red, was quantified from the histology images 
using ImageJ as per our standard procedures [11-14]. Hydroxyproline in tissue was 
quantified by high-performance liquid chromatography (HPLC) analysis of tissue acid 
digests as previously described [19]. Hydroxyproline is expressed as amount per wet weight 
of tissue.
Statistical Analysis
Data are displayed as box plots with the dark band inside the box representing the mean, the 
bottom and top of the box the first and third quartiles, and the whiskers the minimum and 
maximum values. Data are reported as the mean ± standard error. Statistical analyses 
(Analysis of Variance (ANOVA) and Receiver Operating Characteristic (ROC) analysis) 
were performed using Prism 6 (GraphPad Software, Inc, La Jolla, CA) with p<0.05 
considered as significant. Differences among groups were tested with one-way ANOVA 
followed by the Tukey post-hoc test where appropriate.
Results
A respiratory-gated, three-dimensional (3D) inversion recovery (IR) Fast Low Angle Shot 
(FLASH) MRI sequence was used to generate quantitative R1 maps of the entire liver. 
Representative R1 maps generated from data acquired pre and 1-hour post-EP3533 are 
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shown in Fig. 1 for an 18 day BDL rat and a control, sham rat. A dramatic increase in R1 is 
observed following contrast agent injection for the BDL rat, but not the sham rat. As 
demonstrated by the R1 histogram plot (Fig. 1C), the fibrosis is relatively homogenous in 
this particular BDL rat with a standard deviation in R1 throughout the liver of only ±4% (R1 
= 3.16±0.14 s−1). The use of a 3D imaging sequence allowed for the generation of 3D R1 
maps of the entire liver, see for example the movie of the 3D Maximum Intensity Projection 
(MIP) R1 map shown in Supplementary Fig. 2.
Liver fibrosis and disease progression in the BDL rat model was characterized by the 
Collagen Proportional Area (CPA) of histological tissue sections (Fig. 2A-D) and HPLC 
analysis of hydroxyproline content. CPA increased progressively at each time point from 
0.98±0.11% for sham rats, 5.83±0.32% for day 4 BDL rats, 9.33±0.19% for day 10 BDL 
rats, to 14.02±1.02% for day 18 BDL rats (Fig. 2E). Statistically significant differences in 
CPA were observed between sham and day 4, 10 and 18 BDL animals (p<0.0001 all time 
points). Statistically significant differences were also observed between day 4 and day 10 
BDL animals (p=0.0002), between day 4 and day 18 BDL animals (p<0.0001), and between 
day 10 and day 18 BDL animals (p<0.0001). Hydroxyproline content also increased 
progressively with time from 191±9 μg/g for sham rats, 327±16 μg/g for day 4 BDL rats, 
462±35 μg/g for day 10 rats, to 869±89 μg/g for day 18 rats (Fig. 2F). Statistically 
significant differences in hydroxyproline content were observed between sham and day 10 
BDL animals (p=0.001), between sham and day 18 BDL animals (p<0.0001), between day 4 
and day 10 BDL animals (p<0.0001), and between day 10 and day 18 BDL animals 
(p<0.0001). Similarly, the average liver ΔR1 increased progressively with time from 
0.44±0.05 s−1 for sham rats, 0.51±0.08 s−1 for day 4 BDL rats, 0.75±0.09 s−1 for day 10 
rats, to 0.98±0.10 s−1 for day 18 rats (Fig. 2G). Statistically significant differences in ΔR1 
were observed between sham and day 10 BDL animals (p=0.048), between sham and day 18 
BDL animals (p=0.0003), and between day 4 and day 18 BDL animals (p=0.0013).
To assess the ability of ΔR1 to stage liver fibrosis, a receiver-operating characteristic (ROC) 
analysis was performed comparing ΔR1 of rats with different CPA (Fig. 3). Previous work 
has indicated that a CPA cutoff value of 9% was optimal for distinguishing significant from 
severe fibrosis and a cutoff value of 6% was optimal for distinguishing early from 
significant fibrosis [20]. This is in good agreement with our studies where the CPA in rats 
with Ishak ≤1 ranged from 0.5-3%, Ishak ≤3 ranged from 0.5-6%, and Ishak ≤4 ranged from 
0.5-9%. The area under the ROC curve for detecting fibrosis (CPA ≤ 3% versus CPA >3%) 
was 0.84±0.06 (95% CI 0.73-0.95, p=0.0003). The area under the ROC curve for 
distinguishing early (CPA ≤6%) from significant fibrosis (CPA >6%) was 0.94±0.03 (95% 
CI 0.87-1.00, p<0.0001). Finally, the ability of ΔR1 to distinguish significant (CPA ≤9%) 
from severe (CPA >9%) fibrosis stages was analyzed and the area under the ROC curve was 
0.94±0.03 (95% CI 0.87-1.00, p<0.0001). Similar results were obtained for the ROC 
analysis performed comparing ΔR1 of rats with different Ishak scores (Supplementary Fig. 
3), however, in agreement with other studies [20], CPA classification provided higher 
sensitivity and specificity than the Ishak classification.
To assess whether the MRI readout ΔR1 would be sensitive to reporting changes in disease 
in response to therapy, we next investigated the response of BDL rats to rapamycin therapy. 
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While there are no FDA-approved therapies for hepatic fibrosis, previous studies have 
demonstrated that rapamycin is effective in reducing fibrosis in BDL rat models of liver 
fibrosis [16, 17, 21, 22], however, significant variability in response has been observed [16, 
17]. As responses should also vary in upcoming clinical trials of anti-fibrotic therapies, we 
reasoned that this should be an excellent model to determine whether EP-3533 could 
accurately assess diminished fibrosis in response to treatment. Rapamycin treated rats were 
dosed once per day with rapamycin starting on day 4 and imaged on day 18. As shown in 
Fig. 4, a significantly (p=0.0185) decreased ΔR1 was observed for rapamycin treated rats 
(0.64±0.09 s−1) relative to untreated BDL rats (0.98±0.10 s−1). Similarly, significantly 
(p=0.0013) decreased hydroxyproline content (519±59 μg/g, p=0.0013) and significantly 
(p=0.0007) decreased CPA (7.84±1.17%, p=0.0007) were observed relative to untreated 
BDL animals (869±89 μg/g and 14.02±1.02%, respectively).
As expected, there were relatively large standard deviations for the various fibrosis 
biomarkers indicating that there was in fact substantial variability among these outbred rats 
in their response to rapamycin therapy. This was born out by pathological analysis where the 
Ishak scores for the rapamycin treated rats ranged from 1 to 6 and the CPA ranged from 
2.6-14.3%. At day 18, all untreated BDL rats had CPA > 9% (range of 10.3-18.7%). 
Therefore, we defined rats that responded to rapamycin treatment as CPA ≤9% (N=6) and 
non-responders as CPA >9% (N=6). ΔR1 maps and Sirius Red images are shown in Fig. 5 
for representative rapamycin responder and non-responder rats. Box plots of CPA 
demonstrated good separation between responder (3.87±0.55%) and non-responder 
(11.58±0.86%) groups with statistically significant differences between untreated animals 
(14.02±1.02%) and rapamycin responders (p<0.0001) and between rapamycin responders 
and non-responders (p<0.0001). Similarly, box plots of ΔR1 (Fig. 5G) showed a significant 
difference (p=0.03) between rapamycin responder (0.44±0.06 s−1) and non-responder 
(0.83±0.11 s−1) groups and between untreated animals (0.98±0.10 s−1) and rapamycin 
responders (p=0.0009). No statistically significant difference, however, was observed 
between rapamycin non-responder and untreated animals (p=0.61). Finally, as shown in Fig. 
5H, a statistically significant difference (p=0.0005) was observed in the hydroxyproline 
content between rapamycin responder (398±44 μg/g) and untreated animals (869±89 μg/g).
Using the disease progression ROC analysis data from Fig. 3, we set a sensitivity of 90% to 
define the cutoff ΔR1 value (0.71 s−1) to distinguish rats with CPA >9% from CPA ≤9%, 
that is to distinguish non-responders from responders. Using this criterion, we found that the 
ΔR1 value correctly predicted rapamycin response in 11 out of 12 rats compared to the CPA 
standard. The MRI analysis produced only one false negative.
While most rats demonstrated relatively homogeneous R1 throughout the liver (see Fig. 1), 
one of the rapamycin non-responder rats displayed marked heterogeneity in liver fibrosis. 
Representative R1 maps acquired pre- and post EP-3533 are shown in Fig. 6 along with the 
associated R1 histogram plot showing pixelwise R1 values throughout the entire liver. While 
the baseline liver R1 map is relatively homogeneous, the post EP-3533 R1 map shows high 
uptake of probe in the right liver lobe, but a much lower uptake in the left lobe. This is 
readily apparent in the R1 histogram, which shows a bimodal distribution of R1 values (Fig. 
6C). In particular, an elevated ΔR1 is observed in the right liver lobe (ΔR1 = 1.69 s−1) 
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compared to the left liver lobe (ΔR1 = 0.80 s−1), Fig. 6F. This fibrosis heterogeneity was 
confirmed by histology where an elevated CPA was observed for the right liver lobe 
(20.6%) compared to the left liver lobe (12.6%), Fig. 6F. The heterogeneity in the liver 
fibrosis can be appreciated in the 2D orthogonal multi-planar reconstruction of the post-
EP-3533 R1 map shown in Fig. 7.
Discussion
Biopsy is an imperfect gold standard in assessing liver fibrosis as it suffers from limitations 
including intra/inter-observer variability and sampling error as well as complications 
including morbidity and mortality. The clinical need for accurate, non-invasive alternatives 
to liver biopsy is further driven by the growing burden of chronic liver disease worldwide. 
Unfortunately, conventional imaging is also not able to detect fibrosis at a mild or moderate 
stage [10]. However, transient elastography (Fibroscan), which measures liver stiffness, has 
shown promise for the noninvasive staging of fibrosis [23, 24], but still only measures 1/500 
of the liver volume [10].
While great strides in molecular imaging have been made for oncology, neurology and 
cardiovascular disease [25], efforts in the liver and for organ fibrosis have been lacking. 
Here, we take a rationally designed, molecular imaging approach to detect, quantify and 
monitor both disease progression and response to therapy non-invasively and throughout the 
entire liver using MRI and the Type I collagen specific contrast agent EP-3533. Our results 
demonstrate that the change in longitudinal relaxation rate (ΔR1) induced by EP-3533 was 
sensitive to changes in fibrosis during disease progression and can be used to distinguish 
early, intermediate and late stages of fibrosis. AUROC analysis indicated that EP-3533 was 
very effective in distinguishing early and significant fibrosis (CPA≤9%) from severe disease 
(CPA >9%) in this model and comparable to what we observed previously in a mouse CCL4 
model of fibrosis (AUROC = 0.94 vs. 0.94, respectively). On the other hand, distinguishing 
early fibrosis (CPA ≤3% vs. CPA >3%) was less effective in this model compared to the 
CCL4 model (AUROC = 0.84 vs. 0.93, respectively). These differences could be attributed 
to several factors. First, it is possible that EP-3533 is more sensitive to the parenchymal 
fibrosis induced by CCl4-injury as opposed to the biliary fibrosis in response to BDL. 
Second, along those same lines, the CPA scoring used here for comparison should itself be 
more accurate in assessing parenchymal fibrosis as opposed to biliary fibrosis. Alternately, 
the higher resolution achievable on the small animal scanner used for the CCL4 study may 
result in improved sensitivity. Regardless, we could accurately stage biliary fibrosis in this 
study, especially more severe disease, and expect that our results will be even better when 
imaging patients on a clinical scanner.
There are preclinical and clinical trials of a number of anti-fibrotic therapies that interrupt 
several steps in the fibrotic pathway [26-30], but a major obstacle to their drug development 
has been a slow progression of the disease in humans, coupled with a lack of sensitive and 
non-invasive means to assess fibrosis or active fibrogenesis [10]. Together, these factors 
create an enormous cost risk for anti-fibrotic drug development, since clinical trials require 
large patient populations treated for long periods of time to reach a clinically significant 
endpoint. Thus, a biomarker of liver fibrosis that could accurately assess fibrogenesis early 
Farrar et al. Page 7
J Hepatol. Author manuscript; available in PMC 2016 September 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
in treatment would not only be extraordinarily useful in enabling the evaluation of much 
larger pools of candidate therapies in clinical trials, but also might provide the early 
evidence of efficacy needed to incentivize investigators and pharmaceutical sponsors to 
support long-term trials [31].
Here, we show that molecular imaging of collagen with EP-3533 can successfully identify 
decreased disease progression in BDL rats treated with rapamycin. A significantly decreased 
ΔR1 was observed for rapamycin treated animals compared to untreated controls (p=0.02), 
in good agreement with the decreased hydroxyproline content and CPA observed for 
rapamycin treated animals (Fig. 4). Importantly, however, we observed that response to 
rapamycin varied in this outbred strain of rats. Using CPA to classify responders and non-
responders we found 6 rapamycin responder rats (CPA ≤9%) and 6 rapamycin non-
responder rats (CPA >9%). Classification of responders and non-responders was also 
performed using the ΔR1, with ΔR1 correctly identifying response in 11 out of 12 rats (one 
false negative). The one discrepancy observed between ΔR1 and CPA score for assessing 
treatment response points to the difficulty in assessing response with biopsy where error 
rates as high as 33% have been reported [32]. Some of the discrepancies between ΔR1 and 
CPA assessments may be due to heterogeneity in liver fibrosis. Interestingly, we could 
detect heterogeneity within the liver of a rat that received rapamycin (Fig. 6), which not only 
highlights the sensitivity of our technique, but also further demonstrates the need for entire 
liver coverage in order to eliminate the sampling error associated with biopsy.
Recent advanced MRI methods such as magnetic resonance elastography (MRE) and MRI 
relaxation measurements have also demonstrated the benefit of whole liver imaging. For 
example, MRE has observed heterogeneous elastogram values in the liver of patients with 
chronic liver disease [23, 33, 34]. A recent prospective MRE study of non-alcoholic fatty 
liver disease subjects demonstrated similar diagnostic accuracy (AUROC) to our results 
[35]. However, MRE measurements may be compromised in situations where inflammation, 
edema, steatosis and iron-overload are present [36-39]. Similarly, the longitudinal relaxation 
time T1 has recently been reported to be able to stage liver fibrosis [40]. In our study, we 
found that while the pre-contrast T1 did increase with fibrosis (403±9 ms at day 4, 462±12 
ms at day 10, and 508±26 ms at day 18), statistically significant differences in T1 were only 
observed between sham (T1 = 444±11 ms) and day 18 fibrotic rats (p=0.03). We obtained a 
more sensitive measure of fibrosis with EP-3533 molecular imaging as reflected in the 
greater statistical significance between the ΔR1 of sham and fibrotic animals at day 10 
(p=0.048) and day 18 (p=0.0003) time points. This is consistent with our previous study in 
which only a relatively weak correlation (r=0.3, p=0.07) was observed between 
hydroxyproline content and T1 in a CCl4 mouse model of liver fibrosis [14]. Combining the 
various MRI fibrosis biomarkers should, however, provide increased diagnostic accuracy. 
For example, our MRI probes can be combined in the same exam with techniques currently 
used in liver MRI to assess pre-contrast T1 [40], fat content [41] and/or stiffness [42] and 
therefore provide a more comprehensive assessment of liver architecture.
In conclusion, end-stage liver disease currently accounts for one out of every forty deaths 
worldwide and its prognosis remains dismal even as the number of cases continues to rise. 
Strategies that could identify patients at high-risk for progression to cirrhosis and 
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hepatocellular carcinoma (HCC) and/or monitor early responses to anti-fibrotic therapy will 
certainly be crucial going forward not only for successful individualized management of 
disease activity in patients, but also to decrease the mortality associated with this disease. 
Molecular imaging of collagen with EP-3533 should be a useful tool in this regard and 
warrants further investigation in human trials.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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List of abbreviations
MRI magnetic resonance imaging
MRE magnetic resonance elastography
R1 longitudinal relaxation rate
T1 longitudinal relaxation time
TE echo time
TR repetition time
FLASH fast low angle shot
IR inversion recovery
MIP maximum intensity projection
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FOV field of view
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ECM extra-cellular matrix
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ROC receiver operating characteristic
AUROC area under the receiver operating characteristic curve
3D three-dimensional
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Fig. 1. Liver longitudinal relaxation rate (R1) maps
R1 maps acquired (A) pre and (B) 1-hour post EP-3533 of a representative 18-day BDL rat 
and (C) the associated histogram of the liver R1 values pre- (blue) and post EP-3533 (red). 
R1 maps acquired (D) pre and (E) 1-hour post EP-3533 of a representative sham rat and (F) 
the associated histogram of the liver R1 values pre- (blue) and post EP-3533 (red). Much 
greater R1 values were observed post EP-3533 in the liver of the 18-day BDL rat compared 
to the sham rat.
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Fig. 2. Characterization of the Bile Duct Ligation (BDL) rat model of liver fibrosis
Representative Sirius Red histology liver images of (A) sham and BDL rats (B) 4, (C) 10, 
and (D) 18 days after bile duct ligation. (E) Liver fibrosis as assessed by the CPA increased 
progressively with time, with a significant increase relative to sham animals observed at 
days 4, 10 and 18 (****p<0.0001 all time points). (F) Total collagen as assessed by 
hydroxyproline analysis increased progressively with time, with a significant increase 
relative to sham animals observed at days 10 (**p=0.001), and 18 (****p<0.0001). (G) The 
change in longitudinal relaxation rate (ΔR1) induced by EP-3533 increased progressively 
with time, with a significant increase relative to sham animals observed at days 10 
(*p=0.048) and 18 (***p=0.0003).
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Fig. 3. Staging of liver fibrosis by ΔR1
Receiver Operating Characteristic (ROC) analysis demonstrated that ΔR1 could (A) detect 
fibrosis and distinguish CPA ≤3% BDL rats from CPA >3% BDL rats (AUROC=0.84, 
p=0.0003), (B) distinguish early fibrosis (CPA ≤6% ) from significant (CPA >6%) fibrosis 
(AUROC=0.94, p<0.0001), and (C) distinguish significant (CPA ≤9%) from severe (CPA 
>9%) fibrosis (AUROC=0.94, p<0.0001).
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Fig. 4. Response to Rapamycin Therapy
A significant decrease in (A) ΔR1 (*p=0.0185), (B) hydroxyproline content (**p=0.0013), 
and (C) CPA (***p=0.0007) were observed with rapamycin therapy (Rapa) relative to 
untreated BDL animals.
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Fig. 5. Variability in Rapamycin Response
Representative R1 maps from a rapamycin responder (Rapa-R) rat acquired (A) pre and (B) 
post EP-3533 and (C) the associated Sirius Red histology image. Representative R1 maps 
from a rapamycin non-responder (Rapa-NR) rat acquired (D) pre and (E) post EP-3533 and 
(F) the associated Sirius Red histology image. Box plots of the (G) ΔR1, (H) 
hydroxyproline, and (I) CPA responses to rapamycin therapy for responder and non-
responder BDL rats. Significant decreases in ΔR1 (***p=0.0009), hydroxyproline 
(***p=0.0005), and CPA (****p<0.0001) were observed for responder BDL rats compared 
to untreated control rats.
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Fig. 6. Detection of intra-hepatic fibrosis heterogeneity
R1 maps of a non-responder rapamycin rat acquired (A) pre and (B) post EP-3533 
demonstrated striking heterogeneity in liver fibrosis with greater R1 in the right liver lobe 
compared to the left liver lobe. (C) While the pre EP-3533 histogram (blue) of liver R1 
values was homogeneous the post EP-3533 R1 histogram (red) demonstrated a bimodal R1 
distribution. Representative Sirius Red images from the (D) left and (E) right liver lobes 
confirmed the fibrosis heterogeneity with (F) increased CPA for the right liver lobe (20.6%) 
relative to the left liver lobe (12.6%).
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Fig. 7. Three-dimensional assessment of liver fibrosis
Two-dimensional multi-planar reconstruction (MPR) of the three-dimensional post EP-3533 
R1 map demonstrated heterogeneity in liver fibrosis for a rapamycin non-responder rat with 
elevated R1 in the right lobe (rl) and medial lobe (ml) relative to the left lobe (ll). The spine 
(sp), stomach (st) and enlarged bile duct (bd) are also clearly visible.
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